Sign Up Today and Learn More About Aspen Neuroscience Stock
Invest in or calculate the value of your shares in Aspen Neuroscience or other pre-IPO companies through EquityZen's platform.
Aspen Neuroscience Stock (ASNE)
Aspen Neuroscience is a biotechnology company that uses innovative genomic approaches combined with stem cell biology.
About Aspen Neuroscience Stock
Founded
2018
Headquarters
San Diego, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It develops enabling technologies for patient-specific induced pluripotent stem cell-based therapies.
Aspen Neuroscience Press Mentions
Stay in the know about the latest news on Aspen Neuroscience
Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference
prnewswire • Nov 12, 2024
Aspen Neuroscience Expands Cell Manufacturing Capacity
sdbj • Oct 11, 2024
Cell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell processing.
prnewswire • Oct 08, 2024
BRIEF—Aspen Neuroscience expands manufacturing capabilities
thepharmaletter • Oct 02, 2024
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
prnewswire • Aug 05, 2024
Aspen Neuroscience Management
Leadership team at Aspen Neuroscience
Co-Founder & Chief Scientific Officer
Jeanne Loring
Board Member, Seed Investor
Drew Spaventa
Join now and verify your accreditation status to gain access to:
- Aspen Neuroscience current valuation
- Aspen Neuroscience stock price
- Available deals in Aspen Neuroscience and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Aspen Neuroscience stock?
Accredited investors can buy pre-IPO stock in companies like Aspen Neuroscience through EquityZen funds. These investments are made available by existing Aspen Neuroscience shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Aspen Neuroscience stock?
Shareholders can sell their Aspen Neuroscience stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
